Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortization of Deferred ChargesAmortization of GoodwillAmortization of GoodwillAmortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDivestmentsDividends Paid - CommonDividends Paid - CommonFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AdaptHealth (AHCO) Gains from Sales and Divestitures (2020 - 2022)

AdaptHealth has reported Gains from Sales and Divestitures over the past 3 years, most recently at $461000.0 for Q3 2022.

  • Quarterly results put Gains from Sales and Divestitures at $461000.0 for Q3 2022, up 37.61% from a year ago — trailing twelve months through Sep 2022 was $461000.0 (up 37.61% YoY), and the annual figure for FY2021 was $556000.0, up 2.77%.
  • Gains from Sales and Divestitures for Q3 2022 was $461000.0 at AdaptHealth, up from $350000.0 in the prior quarter.
  • Over the last five years, Gains from Sales and Divestitures for AHCO hit a ceiling of $556000.0 in Q4 2021 and a floor of $15417.0 in Q1 2020.
  • Median Gains from Sales and Divestitures over the past 3 years was $230000.0 (2022), compared with a mean of $257037.9.
  • Peak annual rise in Gains from Sales and Divestitures hit 680.0% in 2021, while the deepest fall reached 2.77% in 2021.
  • AdaptHealth's Gains from Sales and Divestitures stood at $541000.0 in 2020, then rose by 2.77% to $556000.0 in 2021, then decreased by 17.09% to $461000.0 in 2022.
  • The last three reported values for Gains from Sales and Divestitures were $461000.0 (Q3 2022), $350000.0 (Q2 2022), and $230000.0 (Q1 2022) per Business Quant data.